Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial.
Joseph ReedTony DongElke EatonJanice FriswoldJodie PorgesSadeer G Al-KindiSanjay RajagopalanIan J NeelandPublished in: Diabetes, obesity & metabolism (2024)
Dexcom G6 CGM was associated with improved glycaemic control and cardiometabolic risk in patients with T2DM who were not on insulin. CGM can be a safe and effective tool to improve diabetes management in patients at high risk for adverse cardiovascular outcomes.
Keyphrases
- type diabetes
- glycemic control
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cardiovascular disease
- insulin resistance
- randomized controlled trial
- emergency department
- stem cells
- study protocol
- patient reported
- mesenchymal stem cells
- skeletal muscle
- bone marrow
- smoking cessation